Binkley N, Borchardt G, Siglinsky E, Krueger D DOES VITAMIN D METABOLITE MEASUREMENT HELP PREDICT 25(OH)D CHANGE FOLLOWING VITAMIN D SUPPLEMENTATION? Endocr Pract. 2017 Apr 2;23(4):432-441. doi: 10.4158/EP161517.OR. Epub 2017 Jan 17.
Blum M, Dallal GE, Dawson-Hughes B Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults. J Am Coll Nutr. 2008 Apr;27(2):274-9.
Borel P, Caillaud D, Cano NJ Vitamin D bioavailability: state of the art. Crit Rev Food Sci Nutr. 2015;55(9):1193-205. doi: 10.1080/10408398.2012.688897. Review.
Chen TC, Shao A, Heath H 3rd, Holick MF An update on the vitamin D content of fortified milk from the United States and Canada. N Engl J Med. 1993 Nov 11;329(20):1507.
Cormick G, Ciapponi A, Cafferata ML, Belizán JM Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015 Jun 30;(6):CD010037. doi: 10.1002/14651858.CD010037.pub2. Review.
Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem. 2009 Jul;42(10-11):1174-7. doi: 10.1016/j.clinbiochem.2009.03.008. Epub 2009 Mar 18.
Gallagher JC, Sai A, Templin T 2nd, Smith L Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):425-37. doi: 10.7326/0003-4819-156-6-201203200-00005. Erratum in: Ann Intern Med. 2012 May 1;156(9):672.
Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003 Jan;77(1):204-10. Erratum in: Am J Clin Nutr. 2003 Nov;78(5):1047.
Holick MF, Shao Q, Liu WW, Chen TC The vitamin D content of fortified milk and infant formula. N Engl J Med. 1992 Apr 30;326(18):1178-81.
Iqbal J, Hussain MM Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1183-94. doi: 10.1152/ajpendo.90899.2008. Epub 2009 Jan 21. Review.
Kazmi SA, Vieth R, Rousseau D Vitamin D3 fortification and quantification in processed dairy products. International Dairy Journal 17:753-759, 2007
Nelson ML, Blum JM, Hollis BW, Rosen C, Sullivan SS Supplements of 20 microg/d cholecalciferol optimized serum 25-hydroxyvitamin D concentrations in 80% of premenopausal women in winter. J Nutr. 2009 Mar;139(3):540-6. doi: 10.3945/jn.108.096180. Epub 2009 Jan 21.
Pedersen JN, Frislev HS, Pedersen JS, Otzen DE Using protein-fatty acid complexes to improve vitamin D stability. J Dairy Sci. 2016 Oct;99(10):7755-7767. doi: 10.3168/jds.2016-11343. Epub 2016 Jul 27.
Shab-Bidar S, Bours SP, Geusens PP, van der Velde RY, Janssen MJ, van den Bergh JP Suboptimal effect of different vitamin D3 supplementations and doses adapted to baseline serum 25(OH)D on achieved 25(OH)D levels in patients with a recent fracture: a prospective observational study. Eur J Endocrinol. 2013 Oct 1;169(5):597-604. doi: 10.1530/EJE-13-0068. Print 2013 Nov.
Thompson GR, Lewis B, Booth CC Absorption of vitamin D3-3H in control subjects and patients with intestinal malabsorption. J Clin Invest. 1966 Jan;45(1):94-102.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.